PUBBLICAZIONI GISCAD

IMPACT FACTOR TOTALE 533,20

Annamaria Ruzzo 1, Francesco Grazia no 2, Francesca Galli 3 et al. 

Sex - Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

· 

Published on-line August 8, 2019 as (2019) 9:11527 | https://doi.org/10.1038/s41598-019-47627-1

S. Cascinu, D. Poli, A. Zaniboni et al.

The prognostic impact of primary tumor location in patients with stage II and stage III colon cancer receiving adjuvant therapy.

A GISCAD analysis from three large randomized trials.

· 

European Journal of Cancer 111 (2019) 1e7

· 

 Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of
Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

Claudio Vernieri, Fabio Galli, Laura Ferrarin... and Maria di Bartolomeo.

On behalf of  TOSCA (Three or Six Colon Adjuvant) Investigators.

Published Ahead of Print on January 3, 2019 as 10.1634/theoncologist.2018-0442

· 

 FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial

Alberto Sobrero, Sara Lonardi, Gerardo Rosati, Maria Di Bartolomeo, Monica Ronzoni, Nicoletta Pella, Mario Scartozzi, Maria Banzi, Maria Giulia Zampino, Felice Pasini, Paolo Marchetti, Maurizio Cantore, Alberto Zaniboni, Lorenza Rimassa, Libero Ciuffreda, Daris Ferrari, Vittorina Zagonel, Evaristo Maiello, Sandro Barni, Eliana Rulli, and Roberto Labianca, on behalf of the TOSCA Investigators

Clin J Oncol 36. © 2018 by American Society of Clinical Oncology - Published at jco.org on April 5

· 

· 

Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis  

Monica Tang, Timothy Jay Price, Jeremy Shapiro, Peter Gibbs, Daniel G. Haller, Dirk Arnold, Marc Peeters, Eva Segelov, Amitesh Roy, Niall Tebbutt, Nick Pavlakis, Chris Karapetis, & Mattew Burge

Expert Review Of Anticancer Therapy, DOI: 10.1080/14737140.2018.1444481

· 

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

A. Grothey, A.F. Sobrero, A.F. Shields, T. Yoshino, J. Paul, J. Taieb, J. Souglakos, Q. Shi, R. Kerr, R. Labianca,J.A. Meyerhardt, D. Vernerey, T. Yamanaka, I. Boukovinas, J.P. Meyers, L.A. Renfro, D. Niedzwiecki, T. Watanabe,*V. Torri, M. Saunders, D.J. Sargent,* T. Andre, and T. Iveson

The new england journal of medicine  March 29, 2018 vol. 378 no. 13

 Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

· 

Riccardo Giampiero, Marco Puzzoni, Bruno Daniele, Daris Ferrari, Sara Monardi, Alberto Zaniboni, Luigi Cavanna, Gerardo Rosati, Nicoletta Pella, Maria Giulia Zampino, Pietro Sozzi, Domenico Germano, Vittorina Zagonel, Carla Codecà, Michela Libertini, Roberto Labianca, Stefano Cascinu, The Italian Group for the Study of Gastrointestinal Cancer (GISCAD) and Mario Scartozzi

British Journal of Cancer (2017), 1-6 | dos: 10.1038/bjc.2017.234

· 

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomized trial comparing two sequences of therapy in colorectal metastatic patients

Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Alberto Zaniboni, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico C. Corsi, Francesco Ferraù, Roberto Labianca, Monica Ronzoni, Mario Scartozzi, Francesca Galli on behalf of GISCAD investigators

European Journal of Cancer 83 (2017) 106e115

Second line with oxaliptalin- or irinotecan-based chemotherapy for gemcitabine-pretrated pancreatic cancer: A systematic review

· 

European Journal of Cancer 81 (2017) 174e182

 Fausto Petrelli, Alessandro Inno, Antonio Ghidini, Lorenza Rimassa, Gianluca Tomasello, Roberto Labianca, Sandro Barni on behalf of GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and Cremona Hospital

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients

A. Ruzzo, F. Graziano,  Fabio Galli, Francesca Galli, E. Rulli, S. Lonardi, M. Ronzoni, B. Massidda, V. Zagonel, N. Pella, C. Mucciarini, R. Labianca, M.T. Ionta, I. Bagaloni, E. Veltri, P. Sozzi, S. Barni, V. Ricci, L. Foltran, M. Nicolini, E. Biondi, A. Bramati, D. Turci, S. Lazzaretti, C. Verusio, F. Bergamo, A. Sobrero, L. Frontini, M. Menghi and M. Magnani

British Journal of Cancer (2017), 1-9 | doi: 10.1038/bjc.2017.289

· 

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab

Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Alberto Zaniboni, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico C. Corsi, Francesco Ferraù, Roberto Labianca, Monica Ronzoni, Mario Scartozzi, Francesca Galli on behalf of GISCAD investigators

European Journal of Cancer 83 (2017) 106e115

FONDAZIONE
GISCAD

GRUPPO ITALIANO PER LO STUDIO DEI 

CARCINOMI DELL'APPARATO DIGERENTE

SEDE

Via Gattinoni, 4

20010 Vanzago (MI)

CONTATTI

Tel. 02 84968409

ufficio.operativo@giscad.it

© 2018 Fondazione GISCAD - P.IVA 05396970963